BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25290314)

  • 21. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
    Bolondi L; Burroughs A; Dufour JF; Galle PR; Mazzaferro V; Piscaglia F; Raoul JL; Sangro B
    Semin Liver Dis; 2012 Nov; 32(4):348-59. PubMed ID: 23397536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of hepatocellular carcinoma in a tertiary Romanian center. Deviations from BCLC recommendations and influence on survival rate.
    Radu P; Groza I; Iancu C; Al Hajjar N; Andreica V; Sparchez Z
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):291-7. PubMed ID: 24078986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A.
    Jung YK; Jung CH; Seo YS; Kim JH; Kim TH; Yoo YJ; Kang SH; Yim SY; Suh SJ; An H; Yim HJ; Yeon JE; Byun KS; Um SH
    J Gastroenterol Hepatol; 2016 Feb; 31(2):467-74. PubMed ID: 26332049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study.
    Vitale A; Morales RR; Zanus G; Farinati F; Burra P; Angeli P; Frigo AC; Del Poggio P; Rapaccini G; Di Nolfo MA; Benvegnù L; Zoli M; Borzio F; Giannini EG; Caturelli E; Chiaramonte M; Trevisani F; Cillo U;
    Lancet Oncol; 2011 Jul; 12(7):654-62. PubMed ID: 21684210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of hepatocellular carcinoma: beyond international guidelines.
    Colombo M; Sangiovanni A
    Liver Int; 2015 Jan; 35 Suppl 1():129-38. PubMed ID: 25529098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.
    Grieco A; Pompili M; Caminiti G; Miele L; Covino M; Alfei B; Rapaccini GL; Gasbarrini G
    Gut; 2005 Mar; 54(3):411-8. PubMed ID: 15710992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma.
    Zhong JH; Ke Y; Gong WF; Xiang BD; Ma L; Ye XP; Peng T; Xie GS; Li LQ
    Ann Surg; 2014 Aug; 260(2):329-40. PubMed ID: 24096763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatocellular carcinoma tumour burden score to stratify prognosis after resection.
    Tsilimigras DI; Moris D; Hyer JM; Bagante F; Sahara K; Moro A; Paredes AZ; Mehta R; Ratti F; Marques HP; Silva S; Soubrane O; Lam V; Poultsides GA; Popescu I; Alexandrescu S; Martel G; Workneh A; Guglielmi A; Hugh T; Aldrighetti L; Endo I; Sasaki K; Rodarte AI; Aucejo FN; Pawlik TM
    Br J Surg; 2020 Jun; 107(7):854-864. PubMed ID: 32057105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database.
    Lee S; Kim BK; Song K; Park JY; Ahn SH; Kim SU; Han KH; Kim DY;
    J Gastroenterol Hepatol; 2016 Apr; 31(4):842-7. PubMed ID: 26513311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study.
    Lee DW; Yim HJ; Seo YS; Na SK; Kim SY; Suh SJ; Hyun JJ; Jung SW; Jung YK; Koo JS; Kim JH; Yeon JE; Lee SW; Byun KS; Um SH
    Liver Int; 2019 Jun; 39(6):1109-1119. PubMed ID: 30972935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers.
    Kimura H; Ohkawa K; Miyazaki M; Sakakibara M; Imanaka K; Tamura T; Sueyoshi H; Takada R; Fukutake N; Uehara H; Ashida R; Ioka T; Nakazawa T; Nakanishi K; Katayama K
    Hepatol Int; 2017 Jan; 11(1):105-114. PubMed ID: 27766479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification.
    Tsilimigras DI; Bagante F; Sahara K; Moris D; Hyer JM; Wu L; Ratti F; Marques HP; Soubrane O; Paredes AZ; Lam V; Poultsides GA; Popescu I; Alexandrescu S; Martel G; Workneh A; Guglielmi A; Hugh T; Aldrighetti L; Endo I; Pawlik TM
    Ann Surg Oncol; 2019 Oct; 26(11):3693-3700. PubMed ID: 31267302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response.
    Guglielmi A; Ruzzenente A; Pachera S; Valdegamberi A; Sandri M; D'Onofrio M; Iacono C
    Am J Gastroenterol; 2008 Mar; 103(3):597-604. PubMed ID: 17970836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of models in patients with hepatocellular carcinoma: comparison of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging system in a Chinese cohort.
    Yan X; Fu X; Cai C; Zi X; Yao H; Qiu Y
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1180-6. PubMed ID: 26067223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluations of seven different clinical staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection].
    Zhao J; Yan T; Huang Z; Bi X; Zhao H; Zhou J; Li Z; Li Y; Li C; Cai J
    Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(12):903-7. PubMed ID: 24854909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective validation of the Barcelona Clinic Liver Cancer staging system.
    Cillo U; Vitale A; Grigoletto F; Farinati F; Brolese A; Zanus G; Neri D; Boccagni P; Srsen N; D'Amico F; Ciarleglio FA; Bridda A; D'Amico DF
    J Hepatol; 2006 Apr; 44(4):723-31. PubMed ID: 16488051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria.
    Wang YY; Zhong JH; Xu HF; Xu G; Wang LJ; Xu D; Wang HW; Wang K; Xiang BD; Mao YL; Li LQ; Xing BC
    Aliment Pharmacol Ther; 2019 Jan; 49(2):202-210. PubMed ID: 30506713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages.
    D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Marti P; Bilbao JI; Martinez-Cuesta A; Benito A; Alegre F; Mauleón E; Herrero JI; Quiroga J; Prieto J; Sangro B
    Ann Surg Oncol; 2011 Jul; 18(7):1964-71. PubMed ID: 21267791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. External validation of a simplified BCLC staging system for early hepatocellular carcinoma.
    Santambrogio R; Salceda J; Costa M; Kluger MD; Barabino M; Laurent A; Opocher E; Azoulay D; Cherqui D
    Eur J Surg Oncol; 2013 Aug; 39(8):850-7. PubMed ID: 23726257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
    Weinmann A; Koch S; Niederle IM; Schulze-Bergkamen H; König J; Hoppe-Lotichius M; Hansen T; Pitton MB; Düber C; Otto G; Schuchmann M; Galle PR; Wörns MA
    J Clin Gastroenterol; 2014 Mar; 48(3):279-89. PubMed ID: 24045276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.